Edwards Lifesciences Beats Q1 Estimates, Raises Full-Year Guidance on TAVR Strength

Edwards Lifesciences (NYSE: EW) delivered a strong first quarter performance that exceeded expectations, prompting management to raise full-year guidance as the structural heart device leader continues to benefit from robust demand for its transcatheter aortic valve replacement (TAVR) products.

Key Numbers

The medical device company reported first-quarter adjusted earnings per share of $0.78, representing a significant beat against consensus estimates. On a GAAP basis, EPS came in at $0.66. Total revenue surged 16.7% year-over-year to $1.65 billion, or 12.7% growth on a constant currency basis, demonstrating strong underlying demand across the portfolio.

The standout performer was Edwards' flagship TAVR segment, which generated sales of $1.20 billion, up 14.4% from the prior year (11.0% constant currency). This growth reflects both healthy market expansion and slight market share gains, particularly in Europe where a competitor exited the market. The company noted that average selling prices remained stable globally throughout the quarter.

Transcatheter Mitral and Tricuspid Therapies (TMTT) contributed $173 million in sales, driven by the company's expanding portfolio of repair and replacement therapies. The Surgical segment added $276 million, growing 10.1% year-over-year (5.9% constant currency) on continued adoption of RESILIA tissue therapies.

Gross profit margin came in at 78.2% on an adjusted basis, compared to 78.7% in the prior year period, with the decline attributed to currency headwinds and increased manufacturing expenses related to new therapy expansion. Operating profit margin reached 31.4% on an adjusted basis, in line with company expectations.

What Management Said

CEO Bernard Zovighian struck an optimistic tone about the company's trajectory, emphasizing that the 12.7% constant currency sales growth "reflects the impact and durability of our focused strategy." He highlighted the company's dedication to "solving large, urgent and complex patient needs" in structural heart disease.

Management pointed to encouraging momentum from the EARLY TAVR study data, which is driving a shift toward more proactive disease management. According to the company, there's an "increased focus on evaluation and intentional referral of patients with severe aortic stenosis earlier in the disease pathway," suggesting a potentially expanding addressable market.

On the competitive front, Edwards noted its global position increased slightly year-over-year, primarily due to a competitor's exit from the European market. The company expressed confidence in maintaining this momentum, citing the "large and growing body of long-term SAPIEN outcomes data" that reinforces physician confidence in the platform.

Regarding the regulatory environment, management highlighted that the Centers for Medicare & Medicaid Services (CMS) is reconsidering the National Coverage Determination for TAVR, which could "improve timely access to lifesaving TAVR therapy" and potentially accelerate adoption.

For the TMTT segment, management emphasized strong physician enthusiasm for the PASCAL transcatheter edge-to-edge repair technology and positive early feedback on the recently FDA-approved SAPIEN M3 for mitral replacement. The company expects to launch PASCAL for tricuspid patients in the U.S. during Q4 2026.

What to Watch

Based on the strong first-quarter performance, Edwards raised its full-year 2026 guidance across multiple metrics. The company now expects constant currency sales growth of 9% to 11% (previously 8% to 10%), translating to total sales of $6.5 to $6.9 billion. TAVR sales growth guidance increased to 7% to 9% from 6% to 8%, implying full-year TAVR sales of $4.7 to $5.0 billion.

The adjusted EPS guidance midpoint was also raised, with the new range of $2.95 to $3.05 compared to the previous $2.90 to $3.05. For the second quarter, management expects sales between $1.66 and $1.74 billion and adjusted EPS of $0.70 to $0.76.

Several catalysts could drive future growth. The PROGRESS trial results studying patients with moderate aortic stenosis will be presented at the TCT conference later this year, potentially opening another patient population. Updated European guidelines from the European Society of Cardiology are already reshaping clinical discussions around proactive disease management.

The company's pipeline remains robust with several launches expected in the coming quarters, including the next-generation PASCAL technology for both mitral and tricuspid patients in Q4, the surgical TRIFORMIS tricuspid valve in the second half of 2026, and a surgical Left Atrial Appendage Closure program later this year.

From a financial position standpoint, Edwards maintains a strong balance sheet with approximately $2.4 billion in cash and cash equivalents against just $600 million in total debt. The company executed a $500 million accelerated share repurchase during the quarter and has $1.5 billion remaining under its authorization, signaling confidence in future prospects.

The raised guidance and multiple product launches on the horizon suggest Edwards is well-positioned to maintain its growth trajectory, though investors will want to monitor competitive dynamics and the pace of TAVR market expansion as more patients are treated earlier in their disease progression.

StockCliff Research